Patient Voices and Clinical Advances: Elinzanetant for Menopause Symptom Management Associated With Breast Cancer Treatment in the OASIS-4 Trial
Failed to add items
Add to basket failed.
Add to wishlist failed.
Remove from wishlist failed.
Adding to library failed
Follow podcast failed
Unfollow podcast failed
Patient Voices and Clinical Advances: Elinzanetant for Menopause Symptom Management Associated With Breast Cancer Treatment in the OASIS-4 Trial
-
Narrated by:
-
By:
In this podcast, a moderator interviews an oncologist and a patient with lived experience of breast cancer on the topic of hot flashes and sleep disturbances in women receiving endocrine therapy for breast cancer treatment. The podcast focuses on key results from the OASIS-4 clinical study of elinzanetant, a dual neurokinin(NK)-1 and NK-3 targeted treatment that blocks the source of hot flashes. Participants reflect on the broader relevance of the results in symptom management, endocrine therapy treatment compliance, and treatment outcomes for patients with breast cancer without compromising their quality of life.
The medicines and indications discussed in this journal are not licensed in all countries, including the United Kingdom. This content is not intended for healthcare professionals in countries where these medicines or indications are not licensed.
Hosted on Acast. See acast.com/privacy for more information.